Sven Wehrwein Sells 25,000 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Sven Wehrwein sold 25,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

AtriCure Price Performance

Shares of ATRC opened at $37.76 on Friday. The firm has a 50-day simple moving average of $31.10 and a two-hundred day simple moving average of $31.34. The stock has a market cap of $1.92 billion, a PE ratio of 179.82 and a beta of 1.24. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $43.18. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.18.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current year.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
• Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
• Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
• Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

Hedge Funds Weigh In On AtriCure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after acquiring an additional 1,230 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the last quarter. Jane Street Group LLC lifted its stake in AtriCure by 658.3% in the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares during the last quarter. Finally, Strs Ohio acquired a new position in AtriCure during the 1st quarter worth approximately $158,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

ATRC has been the subject of several research analyst reports. Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, UBS Group lowered their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, AtriCure currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.